Irisin as a Novel Marker for Insulin Resistance in Iraqi Women with Polycystic Ovary Syndrome Before and After Metformin Therapy

Farhan, Fatin Shallal; Hussein, Shatha Sami

doi:10.1007/s13224-018-1176-7

Cited by 7 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering the association between obesity and irisin levels, Chang et al (24) found higher serum irisin levels in overweight women (BMI higher than 25 kg/m 2 ), independent of their PCOS status, and in overweight PCOS patients from China. Similar ndings have been reported by the other authors (25). In light of these ndings, it has been thought that the brown adipose-differentiation factor irisin might represent a potential biomarker for PCOS, increase the diagnostic accuracy for PCOS, and might be used to improve the metabolic disorder of PCOS (7,8,22,24).…”

Section: Discussionsupporting

confidence: 87%

See 1 more Smart Citation

WITHDRAWN: Exploring Adipsin, Irisin, and Osteopontin as Biomarkers in Polycystic Ovary Syndrome and Their Associations with Metabolic Alterations: A prospective, case-control study

Duzenli,

Yurtcu,

Keyif

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine disorder in premenopausal women, often associated with metabolic alterations. This study aimed to assess adipsin, irisin, and osteopontin levels and correlate the measurements with the metabolic changes in PCOS patients, with a scientific rationale rooted in exploring potential links between these biomarkers and the pathophysiology of PCOS. Methods A prospective, case-control study was conducted on patients diagnosed with PCOS. Group PCOS comprised patients with PCOS, while healthy women were included in Group Control. Serum adipsin, irisin, and osteopontin levels were measured, and various demographic and clinical characteristics and laboratory parameters related to the metabolic status of PCOS were assessed. Results The study included 96 PCOS patients and 80 healthy women. The patients in Group PCOS were significantly younger than those in Group Control (p < 0.001). There were significantly more obese patients in Group PCOS than in Group Control (p = 0.013). PCOS patients had higher serum adipsin (p = 0.020) and lower osteopontin levels (p < 0.001) than healthy women, with obesity and age influencing these differences. The predictive power of osteopontin, with an AUC value of 0.802, was superior to adipsin, with an AUC value of 0.602, in diagnosing PCOS. Besides, osteopontin, in combination with adipsin, had the highest AUC value (AUC = 0.817) than the other dual or triple combinations. Conclusion This study suggests potential links between adipsin, osteopontin, and irisin and PCOS. However, further research is needed to fully understand their roles and clinical implications in PCOS and its associated metabolic changes. The findings highlight the influence of age and obesity on these biomarkers and their relationship with PCOS, shedding light on the complex pathophysiology of the syndrome.

show abstract

Section: Discussionsupporting

confidence: 87%

“…The impact of PCOS on serum irisin levels has been studied previously. Several authors showed higher irisin levels in PCOS women than healthy women (11,(22)(23)(24)(25). They also reported higher irisin levels associated with hyperandrogenic PCOS (23).…”

Section: Discussionmentioning

confidence: 99%

WITHDRAWN: Exploring Adipsin, Irisin, and Osteopontin as Biomarkers in Polycystic Ovary Syndrome and Their Associations with Metabolic Alterations: A prospective, case-control study

Duzenli,

Yurtcu,

Keyif

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…As like previous report in our study population also we did not observe fasting glucose level in diabetic range(70-100 mg/dL normal range of fasting glucose).however when we calculated HOMA-IR which combines the fasting glucose and insulin level, it showed relative insulin resistance (>3) in both obese and non obese PCOS as well as in obese healthy control. As irisin is functionallyrelated to increase insulin sensitivity 19,20 , the observation of relative insulin resistance in obese and non obese PCOS group is consistent with the observation of low irisin level in PCOS.…”

Section: Discussionsupporting

confidence: 86%

Interplay of Low Serum Irisin Level and Insulin Resistance in Obese Polycystic Ovary Syndrome Patients: Potential Biomarker for Pre-clinical Risk Assessment and therapeutic intervention

Verma,

Rajput,

Kishore

et al. 2023

Preprint

View full text Add to dashboard Cite

IntroductionPolycystic Ovary Syndrome (PCOS) is the most frequent endocrine syndrome in women of the reproductive age groupassociated with metabolic syndrome and TypeIIDiabetesMalitus (TIIDM). Purpose of the study was to evaluate if level of serum irisin which is involved in energy metabolism could be used as biomarker for identifying high risk category for pre-clinical detection of diabetes in PCOS.MethodsTotal 27 obese PCOS, 27 non-obese PCOS, and 27 healthy control (HC: 11 obese and 16 non-obese) study subjects between the age group 15-30 years were recruited in the study. Obese and non-obese category was divided based on BMI. Serum irisin, fasting insulin, fasting glucose and other reproductive hormonal profiles were estimated. Cut offs for serum irisin and insulin level were determined based on levels in healthy control.ResultNone of the subject was diagnosed having diabetes at the time of sampling. Both obese and non-obese PCOS showed non-significant lower irisin level than corresponding healthy control (42.27±31.38 vs 51.56±22.7,P=0.4 and 34.89±21.58 vs 40.90±16.444,P=0.4 respectively). However only obese PCOS showed statistically significant association with lower irisin level when median value of the corresponding healthy control was used as cut off (81.5% vs 45%,P=0.047* and 70.3% vs 50%,P=0.21 in PCOS vs HC of obese and non-obese group respectively). Segregating PCOS subjects into two category either normal or below the lower limit of normal serum irisin level(mean-1.64*z of corresponding HC), 100% of obese PCOS subjects having irisin below the lower normal limit showed insulin resistance (>mean+2SD of non obese HC) while the same in obese PCOS subjects having irisin level above the lower limit was only 20% (P=0.006). However no such association was observed in non-obese PCOS subjects when similarly categorized based on irisin level (33% vs 22% respectively,P= 1).ConclusionThe result suggests that obese PCOS with serum irisin level below lower limit of normal range could be segregated as high risk category for closely follow up to detect incidence of diabetes in early time point or taking any preventive measure in early stage. A prospective study with larger sample size is required to substantiate the observation of the pilot study.

show abstract

The “irisin system”: From biological roles to pharmacological and nutraceutical perspectives

2021

View full text Add to dashboard Cite

Irisin as a Novel Marker for Insulin Resistance in Iraqi Women with Polycystic Ovary Syndrome Before and After Metformin Therapy

Cited by 7 publications

References 15 publications

WITHDRAWN: Exploring Adipsin, Irisin, and Osteopontin as Biomarkers in Polycystic Ovary Syndrome and Their Associations with Metabolic Alterations: A prospective, case-control study

WITHDRAWN: Exploring Adipsin, Irisin, and Osteopontin as Biomarkers in Polycystic Ovary Syndrome and Their Associations with Metabolic Alterations: A prospective, case-control study

Interplay of Low Serum Irisin Level and Insulin Resistance in Obese Polycystic Ovary Syndrome Patients: Potential Biomarker for Pre-clinical Risk Assessment and therapeutic intervention

The “irisin system”: From biological roles to pharmacological and nutraceutical perspectives

Contact Info

Product

Resources

About